Paratek Pharmaceuticals — Investor Presentation (June 2016)
12 slides from Paratek Pharmaceuticals's investor presentation, Jun 20, 2016
Slide 1: June 2016 Corporate Overview
June 2016 Corporate Overview Exhibit 99.1
Slide 2: Omadacycline: Broad Spectrum Multi-Indication Oral Targeting Big 3 Community Infection Indications
Omadacycline: Broad Spectrum Multi-Indication Oral Targeting Big 3 Community Infection Indications (1) Pallin DJ, Clinical Infectious Diseases 2009 (2) Decision Resources, 2012 (3) AMR Data 2015 IMS analytics link MIDAS ABSSSI CABP UTI Broad Spectrum for Community-Acquired Resistance Well-tolerated,
Slide 3: Critical Need for a New Broad Spectrum Oral Antibiotic
Critical Need for a New Broad Spectrum Oral Antibiotic ABSSSI: High Resistance Rates to Generic Antibiotics Resistance rates to generic oral broad spectrum antibiotics used for community ABSSSI (9M RX in the U.S.)(6) Common ABSSSI pathogens >80% of all infections(2) TMP/SMX(4) Tetracycline(3) Clinda
Slide 4: Omadacycline Regulatory Strategy
Omadacycline Regulatory Strategy Oral-Only Skin Study Provides Strategic Flexibility P3 ABSSSI Oral-Only P3 ABSSSI IV/Oral SPA Approved 1+1 Strategy P3 ABSSSI IV/Oral P3 CABP IV/Oral Strategic Flexibility: Options 2 & 3 U.S. NDA/sNDA FDA Approval P3 CABP IV/Oral 1+1 NDA 2+1 NDA Skin NDA + CABP sNDA
Slide 5: Omadacycline Potentially Addresses Unmet Needs for UTI
Omadacycline Potentially Addresses Unmet Needs for UTI High Resistance Rates and Fluoroquinolone Safety Concerns Organisms (# Isolates) Levofloxacin Resistant(1) TMP-SMX Resistant(2) Amoxicillin-Clavulanic Acid Resistant(1) E. coli (>4100) 35.2% 39.3% 31.8% E. coli ESBL+ (>790) 76.7% 67.8% 70.2% E.
Slide 6: Omadacycline Phase 1b UTI Study Actively Enrolling
Omadacycline Phase 1b UTI Study Actively Enrolling Imminent Need to Replace Quinolones Group 1 (n=8) Dose A IV Day 1 Dose B Oral q24h Days 2-5 Screening (≤ 48 hours prior to randomization) End of Treatment (Day 6) Post Treatment Evaluation Follow-Up 5 -9 Days Post Last Dose 30 – 37 Days Post First D
Slide 7: Value Proposition: Power of a Broad Spectrum Oral
Value Proposition: Power of a Broad Spectrum Oral “Go Home”: early patient discharge: hospital cost savings “Stay Home”: avoid costly hospitalization Years 1-2: Set the Tone for early adoption and use Hospital Formulary Acceptance Hospital Field Force: ~85 representatives Complementary MSL field for
Slide 8: Omadacycline: Hospitalized ABSSSI
Omadacycline: Hospitalized ABSSSI Broad Spectrum IV to Oral Enables Early Discharge Source: AMR, US only, Full year 2015 (reflects only hospital in-patients) (1)30% will eventually have a defined causative pathogen and receive targeted therapy 33% 23% 20% 33% 23% 20% 20% 23% 18% Targeted (1st line(1
Slide 9: Omadacycline: Hospitalized CABP
Omadacycline: Hospitalized CABP Broad Spectrum IV to Oral Enables Early Discharge Source: AMR, US only, Full year 2015 (reflects only hospital in-patients) (1)30% will eventually have a defined causative pathogen and receive targeted therapy Targeted (1st line(1)) CABP Patients (2.8M U.S.) Broad Spe
Slide 10: Omadacycline: New Broad Spectrum Oral for ABSSSI
Attribute Omadacycline(4) TMP/SMX(1,3) Tetracyclines(2,3) Clindamycin(2,3) Penicillins(2,3) Linezolid(2,3) MRSA Activity Streptococcus Activity Broad Spectrum Convenience of Dosing - - Favorable Oral Tolerability - - Limited Drug Interactions - - No Black Box Omadacycline: New Broad Spectrum Oral fo
Slide 11: Omadacycline Opportunity in UTI
Omadacycline Opportunity in UTI Imminent Need to Replace Quinolones ~4M hospitalized patients ~25M community Rx total Source: AMR Data 2015 IMS analytic link MIDAS
Slide 12: Potential to Treat Antibiotic Resistance for UTI
Attribute Omadacycline(4) Quinolones(1,3) TMP/SMX(2,3) Penicillins (1.3) E. coli Activity ESBL + Activity VRE Activity Renal Excretion Convenience of Dosing - Favorable Oral Tolerability - Limited Drug Interactions - No Black Box Potential to Treat Antibiotic Resistance for UTI (1) JMI surveillance
Paratek Pharmaceuticals — Investor Presentation (June 2016) on 6ix